Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - DiaMedica Therapeutics Inc. | ex_178140.htm |
| EX-31.2 - EXHIBIT 31.2 - DiaMedica Therapeutics Inc. | ex_178139.htm |
| EX-31.1 - EXHIBIT 31.1 - DiaMedica Therapeutics Inc. | ex_178138.htm |
| EX-23.1 - EXHIBIT 23.1 - DiaMedica Therapeutics Inc. | ex_178137.htm |
| EX-21.1 - EXHIBIT 21.1 - DiaMedica Therapeutics Inc. | ex_178136.htm |
| EX-10.19 - EXHIBIT 10.19 - DiaMedica Therapeutics Inc. | ex_178135.htm |
| EX-4.8 - EXHIBIT 4.8 - DiaMedica Therapeutics Inc. | ex_178134.htm |
| EX-4.1 - EXHIBIT 4.1 - DiaMedica Therapeutics Inc. | ex_178133.htm |
| 10-K - FORM 10-K - DiaMedica Therapeutics Inc. | dmtp20191231_10k.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of DiaMedica Therapeutics Inc. (the “Company”) on Form 10-K for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott Kellen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ Scott Kellen | ||
| Scott Kellen | ||
| Chief Financial Officer and Corporate Secretary | ||
| (principal financial officer) | ||
| Minneapolis, Minnesota | ||
| March 23, 2020 |